Compare NIE & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIE | VSTM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.4M | 1.1B |
| IPO Year | N/A | 2011 |
| Metric | NIE | VSTM |
|---|---|---|
| Price | $21.23 | $6.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $17.22 |
| AVG Volume (30 Days) | 68.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $248.46 |
| Revenue Next Year | N/A | $34.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $22.16 | $3.43 |
| 52 Week High | $27.24 | $10.82 |
| Indicator | NIE | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 19.32 | 27.64 |
| Support Level | N/A | $5.26 |
| Resistance Level | $26.93 | $6.48 |
| Average True Range (ATR) | 0.50 | 0.60 |
| MACD | -0.18 | -0.35 |
| Stochastic Oscillator | 0.95 | 0.93 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.